WO2000013740A2 - Manchon radioactif - Google Patents
Manchon radioactif Download PDFInfo
- Publication number
- WO2000013740A2 WO2000013740A2 PCT/US1999/020335 US9920335W WO0013740A2 WO 2000013740 A2 WO2000013740 A2 WO 2000013740A2 US 9920335 W US9920335 W US 9920335W WO 0013740 A2 WO0013740 A2 WO 0013740A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sleeve
- diameter
- radiation
- catheter
- vesicle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
- A61N2005/1004—Intraluminal radiation therapy having expandable radiation sources
Definitions
- the present invention relates to the field of catheter and device-assisted radiation therapy for the prevention of restenosis.
- the response to tissue injury remains one of the major limitations of percutaneous angioplasty procedures and stent placement.
- the response of the vessel wall to the balloon barotrauma, stent placement, placement of a vascular graft (arterial, or arteriovenous graft e.g., dialysis graft) remains a significant limitation of these procedures.
- This response is a complex interaction of inflammation, smooth muscle cell migration, proliferation and myofibroblast transformation that occurs as soon as the barotrauma/trauma occurs and can in a varying number of patients, limit the procedures' success.
- Angioplasty procedures generally involve the introduction of a small balloon catheter into the femoral artery in a patient's leg and, with the help of a guide wire, the catheter is passed by remote manipulation under fluoroscopy into the heart.
- the balloon can then be positioned in a region of a coronary artery that has become constricted due to atherosclerosis and by inflating and deflating the balloon several times the bore of the diseased artery is mechanically widened until a satisfactory blood flow through the vessel has been restored.
- this balloon inflation may also cause some degree of additional injury with local de-endothelialisation and exposure of underlying extracellular matrix components such as collagen and elastin.
- excessive recruitment of platelets and fibrinogen can then result in an acute thrombotic occlusion. This is now less common, however, with the routine use of heparin and aspirin cover during the angioplasty procedure.
- angioplasty procedures produce excellent results obviating the need for bypass surgery, but in about 30 - 40% of patients, an ostensibly successful initial dilatation of the artery may be followed by a renarrowing of the vessel (restenosis) some 3 to 9 months later. If this restenosis is severe, these patients may require a second angioplasty procedure, often with implantation of a stent to act as a scaffold in the vessel. In other cases arterial reconstruction under by-pass surgery, which is a higher risk procedure, may be required. With more than 800,000 PTCA procedures now performed world- wide annually, the socio-economic implication of this 30 - 40% restenosis rate has become a matter of serious concern to interventional cardiologists.
- Endovascular radiation therapy for the prevention of restenosis has become a popular mode of treatment under investigation in cardiovascular medicine.
- Industry is quickly developing an array of delivery systems to facilitate safe delivery and removal of active isotopes delivered endoluminally to the patient, both in the vascular spaces and in other anatomical locations.
- the present invention provides for the use of radiation- emitting agents to prevent and inhibit an undesirable response to vessel wall injury, including restenosis, neointima or cancer.
- the present invention provides the local delivery of radioactive materials to bodily vesicles via a catheter in an expandable and retractable sleeve form.
- the present invention is particularly applicable to the local delivery of radiation-emitting agents during and after interventional cardiology procedures such as angioplasty and stent implantation.
- the present invention provides the improved use of radiation-emitting materials via an expandable and retractable sleeve attached to conventional or specially adapted catheter delivery devices.
- This therapeutic approach is aimed at reducing cellular growth, such as may be due to angiogenesis or cancer, that occurs locally at the site of injury or disease, thus potentially reducing or preventing undesirable responses to injury or disease, such as narrowing, renarrowing or restenosis of veins and arteries.
- the present invention relates to the inhibition of undesirable cellular growth and angiogenesis with a consequent reduction in the delivery and release of 0 2 and substrates of metabolism within the vessel wall and a reduction in the removal of the waste products of metabolism.
- the invention renders the microenvironment unfavorable for migration and proliferation of smooth muscle cells, inflammatory cells and other cells involved in the undesirable response to injury.
- the present invention provides a device for administering radiation to a bodily vesicle, comprising a radiation-emitting sleeve having a generally tubular structure with at least one end adapted for communicating with a distal end of a catheter, wherein the sleeve when in communication with the catheter is expandable from a first positioning diameter to a second larger radiation administration diameter, and is further retractable back to the first positioning diameter.
- the sleeve is sized for delivery within a bodily vesicle.
- the sleeve can have a first positioning diameter of approximately 2 mm and a second administration diameter of approximately 8 mm.
- the sleeve can have a first positioning diameter of approximately 8 mm and a second administration diameter of approximately 14 mm.
- the length of the sleeve can vary, and can preferably be in the range of 5 to 50 mm.
- the invention provides that the radiation-emitting agents are incorporated into a sleeve having a generally tubular form.
- the sleeve can be shaped to receive an expandable portion of a catheter in the proximal end thereof.
- the sleeve can be open or closed at the opposite, or distal, end.
- the sleeve is expandable from a first placement position to a second radiation delivery position, and importantly is capable of contracting back to the first position for withdrawal from the vesicle. Therefore, the sleeve can be constructed from a visco-elastic material, such that it can be expanded when placed over an appropriate delivery catheter, e.g. an angioplasty ballon, and then retract by itself when the delivery catheter is deflated.
- the sleeve can be mechanically expandable and retractable by action of its communication with the attached catheter.
- the present invention provides that radiation-emitting agents can be incorporated into polymers or co-polymers and shaped into sleeve forms, which are capable of expansion and retraction when delivered to the site of interest via an expandable catheter.
- the radiation-emitting agents can be incorporated into metallic sleeve structures, which are capable of expansion and retraction when delivered to the site of interest via a catheter.
- the sleeve can be made radioactive by having the isotope embedded in the sleeve material, or the sleeve can have properties which allow onsite irradiation of the sleeve itself, done specifically at the time of use.
- polymeric materials and methods of fabrication may be used to form the sleeves used in the present invention.
- suitable polymer materials or combinations include, but are not limited to, biocompatible and/or biodegradable polymers such as poly(lactides), polyglycolides, polyanhydrides, polyorthoesters, polyactals, polydihydropyrans, polycyanoacrylates and copolymers of these and polyethylene glycol.
- the radiation-emitting sources include, but are not limited to, those emitting beta, gamma, and X-radiation. It should be understood that any form or radiation that can be used therapeutically can be used in the present invention.
- the amount of radiation-emitting material to be applied is highly variable depending upon the type and efficacy of material selected, the extent of the injury, the condition and responsiveness of the patient, the aggressiveness of the physician's regimen, and so forth. However, the determination of a cellular growth, angiogenesis or restenosis inhibiting effective amount of a radiation-emitting agent in any particular circumstances is within the routine skill of artisans in view of the present disclosure. Further, an appropriate predetermined residence time in the vessel at the site of treatment for delivery of the radiation therapy will be highly variable, however, approximately 2 to 10 minutes is preferred.
- the invention provides methods of administering radiation therapy to a bodily vesicle, comprising inserting into the vesicle the radiation-emitting sleeve having a tubular structure and comprising a proximal end in communication with the distal end of a catheter, wherein the sleeve when in communication with the catheter is expandable from a first positioning diameter to a second larger radiation administration diameter, and is further retractable back to the first positioning diameter.
- the methods further comprise positioning the sleeve at a desired site for radiation therapy within the vesicle; expanding the sleeve to the second radiation delivery diameter; delivering the radiation therapy for a predetermined residence time; retracting the sleeve to the first positioning diameter; and withdrawing the sleeve from the bodily vesicle.
- One particularly advantageous property of this invention is that it answers the problem of eccentric dosing of radiation to the vessel wall. Since delivery of the radiation-emitting agent in the sleeve is circumferential, there is no centering issue or disproportionate dosing in the vessel or cavity.
- This invention also addresses problems related to beta penetration limits, which are problematic within the larger vessels and using conventional radioactive pellets. As the isotope is delivered at the vessel wall by the present invention, there is not a diameter limit for penetrance, as is the case with conventional centered beta delivery systems.
- This invention can be used both for small (approximately 2 to 4 mm) coronary vessels, as well as larger (approximately 4 to 14 mm) aorto/iliac/femoral vessels.
- the present invention includes the use of radiation-emitting agents in an expandable and retractable sleeve for the treatment of the following classes of injuries and diseases including, but not limited to, cancer, atherosclerosis, cardiac transplant vasculopathy, coronary restenosis following coronary intervention including, but not limited to, balloon angioplasty, stent placement, rotablator, and other endoluminal procedures; carotid endarterectomy, stenting and angioplasty, peripheral artery and renal artery angioplasty and stent placement, dialysis graft stenosis (venous or arterial end), and large and small bore graft anastomosis neointima.
- injuries and diseases including, but not limited to, cancer, atherosclerosis, cardiac transplant vasculopathy, coronary restenosis following coronary intervention including, but not limited to, balloon angioplasty, stent placement, rotablator, and other endoluminal procedures; carotid endarterectomy, stenting and angi
- the present invention includes the use of radiation-emitting agents endoluminally in conditions of benign hypertrophy or tissue including benign prostatic hypertrophy, ingrowth of benign liver tissue into stents placed during the TIPS procedure.
- the sleeve of the present invention can also be used to treat undesirable cellular growth, such as tumors, encroaching into the lumen of tubes in the body such as the biliary system, the prostate, the fallopian tubes and ovaries, or the esophagus, for example.
- the present invention relates to the use of radiation-emitting agents in catheter-based devices which answers many problems surrounding radiation delivery systems. It specifically addresses improvement in storage of the radioactive source. It facilitates easy delivery of the source to the treatment site, and storage of the source outside the body with simple removal of the source from the delivery catheter. In addition, the invention provides good vessel or cavity wall penetration with safer, contained use of isotopes, and also provides an easily disposable device once radiation delivery is complete.
- the sleeve of the present invention has a mechanism which allows the user to removably attach the sleeve in expandable and retractable communication with a conventional or specially adapted catheter at the time of delivery, and have a radiation source attached to the delivery catheter, ready for use.
- Such an attachment can be by a variety of well-known means, including one or more tethers, clips, flanges, fasteners or reciprocating threaded portions affixing the sleeve in position on the catheter at one or more points, with the proviso that the attachment does not prevent expansion and retraction of the sleeve.
- the sleeve can also be woven into the distal braids of an expandable wire catheter.
- the catheter delivery system can be a balloon design with locking attachments for the sleeve, or the catheter delivery system can be an expandable mesh or wire braid design. Any catheter design having an expandable distal end will suffice.
- the sleeve can be housed in a small shielded delivery unit, which would be brought to the interventional laboratory (the site of the procedure).
- the catheter when appropriately prepped and tested, would then be inserted into a port in the delivery unit and the sleeve locked in place. It is then placed via guidewire technique to the treatment site.
- dosimetry is complete, the whole system then would be removed, the sleeve detached from the delivery system, the delivery system discarded in the usual manner, and the radioactive sleeve discarded in an appropriate radioisotopic disposal system.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU10904/00A AU1090400A (en) | 1998-09-03 | 1999-09-03 | Radioactive sleeve |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9902498P | 1998-09-03 | 1998-09-03 | |
US60/099,024 | 1998-09-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000013740A2 true WO2000013740A2 (fr) | 2000-03-16 |
WO2000013740A3 WO2000013740A3 (fr) | 2000-06-15 |
Family
ID=22272128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020335 WO2000013740A2 (fr) | 1998-09-03 | 1999-09-03 | Manchon radioactif |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1090400A (fr) |
WO (1) | WO2000013740A2 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840008A (en) * | 1995-11-13 | 1998-11-24 | Localmed, Inc. | Radiation emitting sleeve catheter and methods |
US6001123A (en) * | 1994-04-01 | 1999-12-14 | Gore Enterprise Holdings Inc. | Folding self-expandable intravascular stent-graft |
-
1999
- 1999-09-03 WO PCT/US1999/020335 patent/WO2000013740A2/fr active Application Filing
- 1999-09-03 AU AU10904/00A patent/AU1090400A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001123A (en) * | 1994-04-01 | 1999-12-14 | Gore Enterprise Holdings Inc. | Folding self-expandable intravascular stent-graft |
US5840008A (en) * | 1995-11-13 | 1998-11-24 | Localmed, Inc. | Radiation emitting sleeve catheter and methods |
Also Published As
Publication number | Publication date |
---|---|
AU1090400A (en) | 2000-03-27 |
WO2000013740A3 (fr) | 2000-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Porstmann et al. | Catheter closure of patent ductus arteriosus: 62 cases treated without thoracotomy | |
US5851171A (en) | Catheter assembly for centering a radiation source within a body lumen | |
US5840008A (en) | Radiation emitting sleeve catheter and methods | |
JP4394461B2 (ja) | 重畳構造の被覆ステント | |
US6106454A (en) | Medical device for delivering localized radiation | |
WO1999040972A1 (fr) | Catheter d'application de rayonnement pourvu d'un mecanisme de centrage a serpentin | |
EP1363560A2 (fr) | Appareil et methode permettant de maintenir la circulation dans un vaisseau ou un canal | |
US8945207B2 (en) | Removable stent and method of production | |
US6264596B1 (en) | In-situ radioactive medical device | |
CN102387758B (zh) | 用于具有网的血管内装置的递送系统 | |
EP1177009A1 (fr) | Procedes de realisation d'une endoprothese radioactive | |
US6547812B1 (en) | Radiation therapy using a radioactive implantable device and a radiosensitizer agent | |
CA2820405C (fr) | Stent amovible et procede de fabrication | |
US6575898B2 (en) | Methods and devices for ex vivo irradiation of autologous coronary bypass conduit | |
WO2000013740A2 (fr) | Manchon radioactif | |
JP2002536406A (ja) | 細胞増殖の治療用アルキル化剤 | |
WO2002100473A1 (fr) | Tuteur coronarien et catheter d'administration | |
US20040210300A1 (en) | Apparatus and method for maintaining flow through a vessel or duct | |
Hadjimiltiades et al. | Stenting the distal anastomotic site of the left internal mammary artery graft: a case report | |
Pohl et al. | Angiographic and clinical outcome for the treatment of in-stent restenosis with sirolimus-eluting stent compared to vascular brachytherapy | |
Triller et al. | Vascular endoprostheses (Stents) in the treatment of femoropopliteal vascular occlusions | |
Fontaine et al. | Vascular stent prototype: in vivo swine studies | |
Akhtar et al. | Balloon rupture during stent implantation: A novel technique of salvage with a new manual power injector | |
Sigwart et al. | Percutaneous Transluminal Coronary Stenting: A New Approach to Unresolved Problems in Coronary Angioplasty | |
Beck et al. | A Historical View |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase in: |
Ref country code: AU Ref document number: 2000 10904 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |